Could a repurposed drug boost immune attack on childhood brain tumors?
Disease control
Recruiting now
This early-phase trial is testing whether adding the drug ibrutinib to a chemo-immunotherapy regimen can safely help children and young adults (ages 6–25) with brain cancers that have come back or not responded to standard treatment. The study combines ibrutinib with indoximod an…
Phase: PHASE1 • Sponsor: Theodore S. Johnson • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC